Shares of Intellia Therapeutics Inc. (NTLA) are moving higher on Monday. The reason? The U.S. Food and Drug Administration has decided to get out of the way. The agency lifted a clinical hold on the company's pivotal MAGNITUDE Phase 3 trial, clearing the path for Intellia to resume a late-stage study of its experimental treatment, nexiguran ziclumeran (nex-z), for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). That's a rare and serious heart condition.
This is a reversal from last October, when the FDA slammed the brakes. The agency imposed clinical holds on the applications for both the MAGNITUDE and a related study called MAGNITUDE-2. The trigger was an observation in a patient dosed with nex-z in the MAGNITUDE trial: Grade 4 liver transaminases and increased total bilirubin. In simpler terms, it was a serious liver issue that met the trial's pre-defined criteria for hitting pause. Safety first.
The positive news for Intellia arrives against a gloomy market backdrop, with the Nasdaq having fallen 1.35% on the previous trading day. Sometimes, a company-specific story can buck the trend.
Back in Business
With the hold now lifted on MAGNITUDE, Intellia can get back to work. The goal is to complete enrollment in both this trial and the MAGNITUDE-2 study, which are central to advancing the company's treatment pipeline. The FDA had already removed the hold on the MAGNITUDE-2 trial back in January.
Of course, you don't just restart a trial after a safety scare without some new rules. Intellia says it has aligned with the FDA on a set of mitigation measures. For both trials, this includes enhanced monitoring of liver lab tests, guidance for short-term steroid treatment if elevated liver enzymes are spotted soon after dosing, and excluding patients with certain liver abnormalities upfront.
For the larger MAGNITUDE trial specifically, there are additional guardrails. The company is adding exclusion criteria for patients with a recent history of cardiovascular instability and for those with a very low ejection fraction (less than 25%) at the time of screening. They're trying to enroll a population that can best tolerate the therapy.
So, what are these trials actually testing? The MAGNITUDE trial is the big one, evaluating nex-z in approximately 1,200 patients with ATTR-CM. The smaller MAGNITUDE-2 study is looking at the drug in about 60 patients with a different form of the disease called hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).
What the Charts Are Saying
The market liked the news. The stock was trading about 8.85% above its previous close, a strong move on a positive catalyst. Over the past 12 months, shares are up 20% and are positioned closer to their 52-week highs than their lows, which paints a favorable long-term picture.
Digging into the technical indicators, the Relative Strength Index (RSI) is sitting right at 50.00. That's the definition of neutral—not overbought, not oversold. It's like the market is taking a breath here. Meanwhile, the Moving Average Convergence Divergence (MACD) is at 0.10, which is below its signal line of 0.15. That's a mildly bearish signal, suggesting there might be some underlying selling pressure.
Putting it together, you have neutral momentum from the RSI but a slightly bearish tilt from the MACD. It's a mixed signal, which means traders should keep an eye out for which way the momentum breaks next.
- Key Resistance: $16.50
- Key Support: $14.00
What the Analysts Think: The consensus on the Street remains a Buy. The average price target sits at $19.73. Recent analyst actions show continued optimism:
- Chardan Capital: Maintained a Buy rating with a $26.00 price target (Feb. 27).
- HC Wainwright & Co.: Maintained a Buy rating and raised its price target to $25.00 (Jan. 28).
The Bottom Line: Intellia Therapeutics shares were up 2.69 at $14.15 on Monday, according to market data. For a biotech company, getting a clinical hold lifted is a major hurdle cleared. The path forward for nex-z is now open again, albeit with some new safety signage along the way. Investors are betting that's a road worth traveling.
